A turbine-inspired generator shows how overlooked industrial airflow could quietly become a new source of usable power
Updated
February 12, 2026 4:43 PM
Campus building of Chung-Ang University. PHOTO: CHUNG-ANG UNIVERSITY
Compressed air is used across factories, data centers and industrial plants to move materials, cool systems and power tools. Once it has done that job, the air is usually released — and its remaining energy goes unused.
That everyday waste is what caught the attention of a research team at Chung-Ang University in South Korea. They are investigating how this overlooked airflow can be harnessed to generate electricity instead of disappearing into the background.
Most of the world’s power today comes from systems like turbines, which turn moving fluids into energy or solar cells, which convert sunlight into electricity. The Chung-Ang team has built a device that uses compressed air to generate electricity without relying on traditional blades or sunlight.
At the center of the work is a simple question: what happens when high-pressure air spins through a specially shaped device at very high speed? The answer lies in the air itself. The researchers found that tiny particles naturally present in the air carry an electric charge. When that air moves rapidly across certain surfaces, it can transfer charge without physical contact. This creates electricity through a process known as the “particulate static effect.”
To use that effect, the team designed a generator based on a Tesla turbine. Unlike conventional turbines with blades, a Tesla turbine uses smooth rotating disks and relies on the viscosity of air to create motion. Compressed air enters the device, spins the disks at high speed and triggers charge buildup on specially layered surfaces inside.
What makes this approach different is that the system does not depend on friction between parts rubbing together. Instead, the charge comes from particles in the air interacting with the surfaces as they move past. This reduces wear and allows the generator to operate at very high speeds. And those speeds translate into real output.
In lab tests, the device produced strong electrical power. The researchers also showed that this energy could be used in practical ways. It ran small electronic devices, helped pull moisture from the air and removed dust particles from its surroundings.
The problem this research is addressing is straightforward.
Compressed air is already everywhere in industry, but its leftover energy is usually ignored. This system is designed to capture part of that unused motion and convert it into electricity without adding complex equipment or major safety risks.
Earlier methods of harvesting static electricity from particles showed promise, but they came with dangers. Uncontrolled discharge could cause sparks or even ignition. By using a sealed, turbine-based structure, the Chung-Ang University team offers a safer and more stable way to apply the same physical effect.
As a result, the technology is still in the research stage, but its direction is easy to see. It points toward a future where energy is not only generated in power plants or stored in batteries, but also recovered from everyday industrial processes.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.